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Summary  Synovial  inﬂammation  (synovitis)  frequently  accompanies  intracapsular  pathologic
conditions  of  the  temporomandibular  joint  (TMJ)  such  as  internal  derangement  (ID)  and/or
osteoarthritis  (OA),  and  is  suggested  to  be  associated  with  symptom  severity.  To  identify  the
putative  factors  associated  with  synovitis,  we  investigated  interleukin  (IL)-1-  and/or  tumor
necrosis  factor  (TNF)--responsive  genes  of  ﬁbroblast-like  synoviocytes  (FLS)  from  patients  with
ID  and/or  OA  of  TMJ  using  microarray  analysis.  In  this  review,  we  ﬁrst  summarize  the  FLS  of  TMJ
and  the  signaling  pathways  of  IL-1  and  TNF-.  Next,  we  show  the  up-regulated  genes  in  FLS
after  stimulation  with  IL-1  or  TNF-,  and  summarize  the  gene  functions  based  on  recent  stud-
ies.  Among  the  top  10  up-regulated  factors,  molecules  such  as  IL-6  and  cycrooxygense-2  have
been  well  characterized  and  investigated  in  the  inﬂammatory  responses  and  tissue  destruc-
tion  associated  with  joint  diseases  such  as  RA  and  OA,  but  the  roles  of  some  molecules  remain
unclear.  The  FLS  reaction  can  lead  to  the  synthesis  and  release  of  a  wide  variety  of  inﬂam-
matory  mediators.  Some  of  these  mediators  are  detected  in  joint  tissues  and  synovial  ﬂuids
under  intracapsular  pathologic  conditions,  and  may  represent  potential  targets  for  therapeutic
interventions  in  ID  and/or  OA  of  TMJ.
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1. Introduction
The  temporomandibular  joint  (TMJ)  is  one  of  the  most
complex and  active  joints  in  the  human  body,  playing
an important  role  in  functions  such  as  speaking,  chewing
and swallowing.  Patients  with  tempormandibular  disorders
(TMD) most  frequently  present  with  pain,  limited  mandibu-
lar motion  and  TMJ  sounds.  However,  TMD  are  deﬁned  as
a subgroup  of  craniofacial  pain  problems  that  involve  the
TMJ, masticatory  muscles  and  associated  head  and  neck
musculoskeletal structures.  The  details  and/or  taxonomy  of
TMD have  been  reported  in  other  review  papers  [1—3].  It
is necessary  to  carry  out  systematic  investigations  into  the
development and  progression  of  this  disease.  We  have  inves-
tigated the  crucial  factors  in  the  intracapsular  pathologic
condition of  TMJ.
Recently, the  accumulation  of  arthroscopic  [3—6]  and
magnetic resonance  imaging  ﬁndings  [7,8],  histological  stud-
ies [4,9]  and  synovial  ﬂuid  analysis  [10—13]  have  led  to
an increase  in  knowledge  that  may  contribute  to  under-
standing the  intracapsular  pathologic  conditions  of  TMJ,
such as  internal  derangement  (ID),  disc  displacement  (DD),
ﬁbrous adhesions,  synovial  inﬂammation  (synovitis)  and
osteoarthritis (OA).  These  entities  are  not  mutually  exclu-
sive and  may  coexist.  Synovitis  frequently  accompanies
TMJ ID  and/or  OA  [5,6].  In  orthopedics,  synovitis  has  been
suggested to  be  a  key  feature  of  OA  [14],  although  the
relationship between  synovitis  and  OA  is  not  well  deﬁned.
On the  other  hand,  numerous  mediators  contribute  to  both
inﬂammatory and  degradative  pathways  associated  with  the
progression of  the  pathologic  condition  in  the  joints  such  as
OA and  rheumatoid  arthritis  (RA)  [15—17].
Inﬂammatory  factors  have  been  detected  in  the  synovial
ﬂuids and/or  tissues  from  patients  with  ID  and/or  OA  of
inﬂammation  and  tissue  destruction  in  intracapsular
pathological conditions,  but  little  is  known  about  the
molecular mechanisms  that  underlie  the  development  of
the pathologic  condition.  To  understand  the  molecular
mechanisms underlying  the  role  of  these  factors  in  the
pathologic condition,  it  is  necessary  to  elucidate  the
signaling pathways  and  molecular  network.
In  order  to  identify  the  putative  factors  associated  with
the intracapsular  pathologic  condition,  we  investigated
interleukin (IL)-1-  and/or  tumor  necrosis  factor  (TNF)-
-responsive genes  of  synoviocytes  from  patients  with  ID
and/or OA  of  TMJ  [19—26].  According  to  microarray  anal-
ysis, a  large  number  of  IL-1-  and/or  TNF--responsive
genes of  synoviocytes  were  detected  [19—21].  All  of  the
responsive genes  cannot  be  introduced  and  discussed  in
this review.  Therefore,  this  review  will  address  the  top  10
genes up-regulated  in  synoviocytes  after  treatment  with
IL-1- or  TNF-,  and  will  then  summarize  current  knowl-
edge regarding  the  functional  roles  of  these  inﬂammatory
signaling networks.
2.  Synovium and synoviocytes
The  articular  surfaces  involved  in  the  TMJ  are  the  articu-
lar eminence  of  the  temporal  bone  and  mandibular  condyle
[2,27]. The  articular  surface  of  joints  such  as  the  knee  is
covered with  hyaline  cartilage,  whereas  in  TMJ,  the  articu-
lar lining  consists  of  ﬁbrocartilage.  The  TMJ  is  covered  with
a ﬁbrous  capsule  known  as  the  synovial  membrane,  synovial
tissues or  synovium.  Synovial  membrane,  which  consists  of
the synovial  lining  layer  and  the  connective  sublining  layer,
lines all  intra-articular  non-loaded  structures,  except  for
articular cartilage  of  the  eminence,  fossa  and  mandibularTMJ [10—13]  and  from  animal  TMJ  inducing  inﬂammation
using antigens  such  as  ovalbumin  [18].  These  studies  have
suggested that  over-production  of  inﬂammatory  molecules
is a  crucial  event  in  mediating  the  acute  and  chronic
c
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Tondyles, and  the  articular  disc  [27,28].
The  synovial  membrane  comprises  synoviocytes  for  the
roduction/secretion and  resorption  of  synovial  ﬂuids.
here are  two  different  types  of  cell  in  the  synovial  lining
1o
t
o
c
l
d
u
m
p
a
c
u
d
g
t
e
a
m
i
i
t
3
F
p
o
W
u
a
a
t
a
i
[
d
r
t
i
c
p
3
I
c
s
w
a
r
(
t
g
I
d
a
m
B
d
r
H
n
a
p
r
e
I
i
N
3
T
s
m
t
ﬁ
i
m
b
F
t
T
(
i
v
a
M
d
c
a
d
c
4
F
T
r
G
T
g
w
i
r
w
m
f
b
w
a
(
42  
f  the  knee;  macrophage-like  type  cells  and  ﬁbroblast-like
ype cells  [29].  The  synovial  membrane  in  TMJ  also  consists
f macrophage-like  type  A  cells  and  ﬁbroblast-like  type  B
ells  [30—32].  It  has  been  reported  that  the  macrophage-
ike type  A  cells  are  ultrastructurally  characterized  by
ense ﬁlopodia-like  surface  folds,  numerous  vesicles,  vac-
oles and  lysosomes,  and  are  regarded  as  being  of  a
acrophage lineage  with  phagocytic  activity  [30—33].  It  is
lausible that  macrophage-like  type  A  cells  are  derived  from
 monocyte-lineage  and  have  high  migratory  and  phago-
ytic activity.  In  contrast,  ﬁbroblast-like  type  B  cells  are
ltrastructurally characterized  by  the  presence  of  a  well-
eveloped rough  endoplasmic  reticulum  and  dense  secretory
ranules [30—32].  It  has  been  suggested  that  ﬁbroblast-like
ype B  cells  produce  and  secrete  both  synovial  ﬂuids  and
xtracellular matrix  components,  such  as  collagen,  as  well
s a  number  of  putative  mediators  of  inﬂammation.  Both
icrophage-like type  A  and  ﬁbroblast-like  type  B  cells  have
mportant roles  in  homeostasis  and  pathologic  conditions  in
ntracapsular TMJ.  However,  little  is  known  about  the  func-
ion and  response  of  these  synoviocytes  in  TMJ.
. In vitro model for synovitis
ibroblast-like  synoviocytes  (FLS)  that  were  positive  for
ropyl 4-hydroxylase  and  vimentin  can  be  isolated  from  syn-
vium as  biopsy  specimens  by  arthroscopic  surgery  [25].
e investigated  IL-1-  or  TNF--responsive  genes  in  FLS
sing microarray  analysis  to  identify  the  putative  factors
ssociated with  synovitis  in  TMJ.  IL-1  and  TNF-,  which
re pleiotropic  cytokines,  have  been  shown  to  play  impor-
ant roles  in  both  immune  reactions  and  inﬂammation,
s well  as  in  pain  response  and  cartilage/bone  remodel-
ng, particularly  cartilage  degradation  and  bone  resorption
33—36]. These  cytokines  have  been  widely  studied  in  the
evelopment of  joint  pathologic  conditions  such  as  OA  and
heumatoid arthritis  (RA)  [14,37].  It  has  also  been  reported
hat the  levels  of  IL-1  and  TNF-  are  signiﬁcantly  higher
n synovial  ﬂuids  from  patients  with  ID  and  OA  in  TMJ,  as
ompared to  healthy  TMJ  [10,12].  The  signal  transduction
athways of  IL-1  and  TNF-  are  shown  in  Figs.  1  and  2.
.1.  IL-1
L-1  comprises  IL-1  and  IL-1,  and  is  produced  by  various
ell types,  such  as  macrophages,  ﬁbroblasts,  osteoblasts  and
ynoviocytes [38].  The  details  of  the  IL-1  signaling  path-
ays have  been  reported  [39,40].  As  shown  in  Fig.  1,  the
ctivating IL-1  receptor  is  a  complex  of  two  chains,  IL-1
eceptor type  I  (IL-1RI)  and  IL-1  receptor  accessory  protein
IL-1RAcP). The  binding  of  IL-1  to  IL-1R  complex  leads  to
he recruitment  of  myeloid  differentiation  primary  response
ene 88  (MyD88),  an  adaptor  protein  that  in  turn  recruits
L-1 receptor  associated  kinases  (IRAKs).  The  subsequent
issociation of  these  kinases  from  the  receptor  complex
nd recruitment  of  downstream  signaling  molecules,  ulti-
ately results  in  activation  of  the  nuclear  factor  kappa (NFB)  and  MAPK  (p38  JNK,  and  ERK)  pathways.  IL-1RII
oes not  possess  a  signal  transduction  domain,  and  the
esulting heterodimeric  receptor  complex  is  non-signaling.
ence, sequestration  of  IL-1  and  the  co-receptor  IL-1RAcP
A
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egatively  regulates  IL-1RI-mediated  signaling.  IL-1  receptor
ntagonist (IL-1Ra)  also  inhibits  IL-1  signaling.
Both  IL-1  and  IL-1  were  detected  in  synovial  ﬂuids  from
atients with  ID  and  OA  of  TMJ  [41],  but  IL-1  is  typically
eported. On  microarray  analysis,  IL-1  was  predominantly
xpressed in  FLS  when  compared  to  IL-1  (data  not  shown).
n addition,  expression  of  IL-1  and  IL-1  were  up-regulated
n FLS  by  treatment  with  IL-1,  which  may  be  mediated  by
FB activation  (data  not  shown).
.2.  TNF-
NF-  is  produced  in  response  to  pathological  conditions
uch as  inﬂammation  and  infection,  mainly  by  activated
acrophages and  T  lymphocytes,  but  also  by  several  cell
ypes including  natural  killer  (NK)  cells,  mast  cells  and
broblasts. Macrophages  are  the  primary  source  of  TNF  in
nﬂamed synovial  tissue  [41],  and  TNF-  is  related  to  both
acrophage migration  and  pain  in  inﬂammatory  joints  [42].
The  details  of  the  TNF-  signaling  pathway  have  also
een reported  in  other  review  papers  [43—46].  As  shown  in
ig. 2,  binding  of  ligand  TNF-  to  its  receptor  TNFR1  leads  to
he recruitment  of  TNFR-associated  death  domain  (TRADD).
RADD also  interacts  with  TNF  receptor  associated  factor
TRAF) 2,  followed  by  sequential  recruitment  of  receptor
nteracting protein  (RIP),  and  then  subsequent  kinase  acti-
ation. TNF-  triggers  several  signaling  cascades  such  as
poptotic pathways,  activation  of  NFB  and  MAPKs  (p38
APK, ERK  and  JNK).  TRADD  directly  binds  to  Fas-associated
eath domain  protein  (FADD)  and  activates  apoptosis  via
aspase cascade.  On  the  other  hand,  cell  signaling  associ-
ted with  TNFR2  is  poorly  understood.  TNFR2  lacks  a  death
omain, despite  interacting  with  TRAF2,  through  which  it
an activate  the  transcription  factors  NFB  and  AP-1.
. IL-1- or TNF--responsive genes
LS  were  treated  with  or  without  0.1  ng/ml  IL-1  or  10  ng/ml
NF- for  4  h,  and  total  RNA  was  then  extracted  for  microar-
ay analysis.  Expression  of  8,793  genes  on  the  Human
enome Focus  Array  (Affymetrix)  in  control  and  IL-1-  or
NF--stimulated cells  was  then  compared.  A  total  of  212
enes showed  greater  than  2-fold  up-regulation  by  IL-1,
hile 239  genes  were  up-regulated  genes  by  at  least  2-fold
n the  presence  of  TNF-  [20].  Table  1  lists  the  top  10  up-
egulated genes  in  FLS  treated  with  IL-1  or  TNF-.  There
ere ﬁve  genes  that  overlapped  between  the  two  treat-
ents, and  MIP-3,  which  is  a  member  of  the  chemokine
amily, was  found  to  be  the  most  strongly  up-regulated  gene
y both  IL-1  and  TNF-.  In  addition,  MIP-3  production
as decreased  by  treatment  with  inhibitors  against  MAPK
nd NFB  signaling  in  both  IL-1-  and  TNF--stimulated  cells
Table 2).
.1.  Chemokiness  shown  in  Table  1,  numerous  chemokine  family  mem-
ers are  listed  among  the  top  10  up-regulated  genes
n FLS  treated  with  pro-inﬂammatory  cytokine;  six
hemokines with  IL-1-stimulation  and  ﬁve  chemokines  with
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Figure  1  IL-1  signaling.  The  IL-1  signaling  complex  is  assembled  when  IL-1  binds  to  its  receptor,  IL-1RI.  The  heterodimeric  receptor
complex  consisting  of  IL-1RI  and  IL-1RAcP  leads  to  the  recruitment  of  MyD88  and  IRAKs.  Subsequently,  IRAK4  phosphorylates  IRAK1.
These  events  lead  to  the  activation  of  the  NFB  pathway  by  providing  a  platform  for  the  recruitment  of  TGF--activated  kinase  1
(TAK1,  a  MAPK  kinase  kinase)  and  the  IKK  complex.  TAK1  activates  IKK2,  which  in  turn  phosphorylates  IB,  thereby  freeing  NFB.
On  the  other  hand,  TAK1  also  phosphorylates  MAPK  kinases  such  as  MKK3/6  and  MKK4/7,  and  then  phosphorylate  MAPKs.  MAPKs  also
activate  several  transcription  factors,  such  as  AP-1.
Table  1  Up-regulated  genes  after  treatment  with  IL-1  or  TNF-.
Rank  IL-1  TNF-
Gene  GenBank  Fold  Gene  GenBank  Fold
1  CCL20  (MIP-3)  NM  004591  429.9  CCL20  (MIP-3)  NM  004591  322.2
2  CXCL3  (GRO-)  NM  002090  150.4  IL-8  (CXCL8)  AF043337  76.7
3  CSF2  M11734  107.4  CSF2  M11734  37.9
4  IL-8  (CXCL8)  AF043337  89.8  ICAM1  NM  000201  32.1
5  CXCL1  (GRO-)  NM  001511  59.5  CXCL3  (GRO-)  NM  002090  31.1
6  CXCL2  (GRO-)  M57731  50.1  CXCL10  (IP10)  NM  001565  27.8
7  IL-6  NM  000600  40.1  BCL2A1  NM  004049  24.5
8  PTGS2  (COX-2) NM  000963  37.8  GCH1  NM  000161  21.9
9  BCL2A1  NM  004049  37.3  IL17RB  NM  019583  21.9
10  CXCL10  (IP10)  NM  001565  28.7  CX3CL1  (ﬂactalkine)  U84487  21.6
Source: Akutsu et al. [20].
Rank;  ranking of up-regulated genes with IL-1 or TNF-. Fold; average normalized intensity of stimulated FLS/average normalized
intensity of control FLS. Three FLSs, which were isolated from three patients, were experimented independently.
14  N.  Ogura,  T.  Kondoh
Figure  2  TNF-  signaling.  Binding  of  TNF-  to  TNFRI  results  in  activation  of  its  receptors,  followed  by  recruitment  of  adaptor
proteins (TRADD,  FADD,  TRAF  and  RIP)  in  a  sequential  manner  that  activates  several  signaling  cascades  leading  to  the  activation
of  transcription  factors  NFB,  AP-1  and/or  caspase  cascades.  TNFRI  has  a  so-called  death  domain  region,  which  is  essential  for
induction  of  apoptosis  through  the  activation  of  caspase  cascades.  TNFRII  does  not  have  the  death  domain.  As  compared  with
TNF-R1,  the  function  of  TNFRII  is  less  well  understood.
Table  2  Effects  of  inhibitors  on  MIP-3  production.
Inhibitor  IL-1  TNF-
MIP-3  (pg/105 cells)  %  inhibition  MIP-3  (pg/105 cells)  %  inhibition
None  118.0  ±  27.2  0  482.1  ±  223.2  0
PD98059  (ERK1/2)  43.8  ±  15.2  63  142.7  ±  23.2  70
SB203580  (p38)  19.7  ±  4.0  83  115.8  ±  17.9  76
SP600125  (JNK)  14.6  ±  8.5  88  80.8  ±  11.9  83
APDC  (NFB)  15.3  ±  1.9  87  17.2  ±  3.8  96
Source: Akutsu et al. [20].
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0.1 ng/ml IL-1 or 10 ng/ml TNF- for 3 h. Results are expressed a
NF--stimulation.  Chemokines  are  small,  chemoattrac-
ant cytokines  that  play  key  roles  in  the  accumulation  of
nﬂammatory cells  at  the  site  of  inﬂammation  [47—49].
hemokines are  classiﬁed  into  four  groups  based  on  the
otif displayed  by  the  ﬁrst  two  cysteine  residues  near  the
-terminus (CC,  CXC,  C  and  CX3C),  and  their  receptors  are
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hemokines act  through  seven  transmembrane  G-protein
oupled receptors  that  are  expressed  selectively  on  the  sur-
ace of  speciﬁc  leucocyte  and  lymphocyte  subsets  [47].  The
XC chemokines  mainly  act  on  neutrophils  and  lymphocytes,
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lymphocytes  [48,49].  Chemokines  are  considered  key  play-
ers in  the  diapedesis  of  leukocytes  from  the  vasculature  into
tissues in  inﬂammatory  diseases.  In  TMJ,  inﬂammatory  cells
were also  increased  in  synovial  tissues  from  not  only  RA  and
OA [50],  but  also  ID  [51].
It  has  been  shown  that  chemokines  such  as  IL-8/CXCL-
8, MCP-1/CCL-2  and  RANTES/CCL-5  are  expressed  by  human
chondrocytes and  synoviocytes  isolated  from  patients  with
OA and  RA  [52,53].  Several  chemokines,  such  as  IL-8/CXCL8,
GRO-a/CXCL1, RARES/CCL5  and  MIP-1/CCL3,  are  increased
in synovial  tissue  and  synovial  ﬂuid  from  RA  and  OA,
as compared  to  healthy  controls  [49,54,55].  IL-8/CXCL8
and MCP-1/CCL2  are  also  elevated  in  synovial  ﬂuids  from
patients with  ID  and/or  OA  of  TMJ  [12,21,41].
Inﬂammatory  arthropathies  are  characterized  histologi-
cally by  inﬁltration  of  inﬂammatory  cells  and  enlargement
of the  synovial  lining  layer  [55].  Accumulation  of  neu-
trophils and  macrophages  in  inﬂamed  synovial  tissues  may
lead to  signiﬁcant  structural  damage  to  joints  with  arthri-
tis [52,55].  Inﬂammatory  cells  have  also  been  detected  in
synovial tissue  and  in  ﬂuid  from  patients  with  intracapsular
pathologic condition  of  the  TMJ  [50,56].  The  mechanisms
leading to  cellular  inﬁltration  of  the  synovium  and  joint
degeneration have  been  elucidated  to  a  degree  by  study-
ing the  release  of  degradative  enzymes,  various  products
of oxidative  metabolism  and  inﬂammatory  cytokines.  The
following sequence  of  events  is  consistent  with  these  ﬁnd-
ings: (1)  chemokines  produced  by  FLS  stimulate  chemotaxis
of neutrophils,  macrophages  and  T-lymphocytes;  (2)  these
inﬂammatory cells  produce  inﬂammatory  cytokines  such
as IL-1,  matrix  degradative  enzymes  and  various  prod-
ucts of  oxidative  metabolism;  (3)  enzymes  and  oxidative
metabolites cause  degradation  of  the  extracellular  matrix;
and (4)  inﬂammatory  cytokines  stimulate  FLS  to  produce
more chemokines.  Furthermore,  the  subset  of  CXC-type
chemokines that  contain  the  sequence  Glu-Leu-Arg  (the
‘‘ELR’’ motif)  are  also  thought  to  promote  angiogenesis  [57].
Thus, induction  of  ELR-CXCs  such  as  CXCL1,  2,  3,  6,  and  8
may lead  to  both  recruitment  of  inﬂammatory  cells  and  new
small vessels  in  synovial  tissues.  Although  chemotaxis  is  a
necessary function  of  homeostasis,  inappropriate  inﬁltration
of inﬂammatory  cells  may  lead  to  joint  degeneration.
4.2.  IL-6
IL-6  was  ranked  7  among  the  top  10  up-regulated  genes  in
FLS treated  with  IL-1  (Table  1).  In  contrast,  IL-6  was  not
found among  the  top  10  up-regulated  genes  with  TNF-  (it
was ranked  16;  data  not  shown).  IL-6,  which  is  produced  by
T-cells, B-cells,  monocytes,  ﬁbroblasts,  endothelial  cell  and
FLS, is  considered  to  play  a  central  role  in  chronic  inﬂam-
mation and  is  expressed  in  excess  at  sites  of  inﬂammation
[58,59]. IL-6  plays  an  important  role  in  RA  inﬂammation.  IL-6
levels are  markedly  elevated  in  the  serum  and  the  synovial
ﬂuid of  RA  patients,  and  this  elevation  has  been  directly
correlated with  clinical  indices  of  disease  activity  [60,61].
In addition,  high  levels  of  soluble  IL-6  receptor  (sIL-6R)  have
been shown  to  correlate  with  the  degree  of  joint  destruc-
tion, particularly  in  advanced  stages  of  RA  [62].  In  ID  and  OA
of TMD,  IL-6  is  detected  in  the  synovial  ﬂuids  from  patients,
and IL-6  levels  are  positively  correlated  with  the  degree  of
t
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ynovitis  [10,63].  IL-6  levels  are  an  indicator  of  unsuccessful
utcome of  TMJ  irrigation  by  arthrocentesis  [64].  In  addi-
ion, sIL-6R  was  also  detected  in  synovial  ﬂuids  from  patients
ith ID  or  OA  [65].
IL-6 exerts  its  biological  activity  through  two  molecules;
ype I  transmembrane  IL-6  receptor  (IL-6R)  and  transmem-
rane signal  transducer  protein  gp130  (gp130)  [59].  IL-6R  is
mportant for  ligand  binding  and  is  able  to  play  only  a  minor
ole in  signal  transduction.  gp130  contains  several  poten-
ial motifs  for  intracellular  signaling  for  JEK/STAT  and  ERK
66]. The  soluble  type  receptor  (sIL-6R)  binds  to  its  ligand
L-6, forming  a  complex  with  gp130  [59].  The  complex  of
L-6/sIL-6R/gp130 is  able  to  induce  signal  transduction  in
arget cells,  although  other  soluble  receptors,  such  as  the
eceptors for  IL-1  or  TNF,  are  known  to  inhibit  the  effects  of
heir ligands  [67].  Therefore,  the  population  of  potential  IL-
 target  cells  is  strongly  increased  by  the  presence  of  sIL-6R.
ctivation of  cells  that  only  express  gp130  via  the  IL-6/sIL-
R complex  is  known  as  trans-signaling,  whereas  activation
f cells  via  membrane-bound  IL-6R  in  complex  with  IL-6  is
nown as  classic  signaling.
IL-6  elicits  the  development  of  speciﬁc  cellular  and
umoral immune  responses.  IL-6  is  identiﬁed  as  a  B-cell  dif-
erentiation factor  [68].  IL-6  enhances  the  proliferation  and
ctivation T-cells  [69].  Th17  helper  cells  of  the  T-cell  subset,
hich produce  IL-17  in  autoimmune  pathology,  differentiate
rom naïve  CD4+  T-cells  by  IL-6  stimulation  [70].  IL-6  also
nduces the  transmigration  of  neutrophils  to  inﬂammatory
ites in  arthritis  by  stimulating  chemokine  production  in  var-
ous cell  types  [71].  There  is  substantial  evidence  that  IL-6
lays an  important  role  in  rheumatoid  inﬂammation  [58].
In  addition,  IL-6  is  suggested  to  have  a  pathogenetic
ole in  abnormal  bone  resorption  in  RA  [72].  IL-6  induces
bnormal osteoclastogenesis  in  the  inﬂamed  joints  of  RA
ia the  induction  of  RANKL  expression  in  osteoblasts  and
ynoviocytes [72,73].  With  regard  to  joint  cartilage,  matrix
etalloproteinase (MMP)  and  a  disintegrin  and  metallopro-
einase with  thrombospondin  motifs  (ADAMTS)  are  thought
o play  crucial  roles  in  cartilage  matrix  degradation.  IL-6
nduces the  production  of  MMPs  (MMP-1,  MMP-3  and  MMP-
3) and  ADAMTS-4  from  chondrocytes  [74].  These  ﬁndings
uggest that  IL-6  plays  a number  of  critical  roles  in  the
athogenesis of  joint  diseases.
We  have  shown  that  FLS  constitutively  expresses  gp130,
ut not  IL-6R  (Fig.  3)  [75].  In  contrast,  sIL-6R  was  detected
n synovial  ﬂuids  from  patients  with  ID  and/or  OA  of  TMJ
65]. In  the  interacapsular  pathologic  condition  of  TMJ,  MMP
roduction  may  be  enhanced  in  FLS  through  the  IL-6/sIL-
R/gp 130  complex,  as  sIL-6R  exists  in  synovial  ﬂuids  and  IL-6
s produced  by  FLS  in  the  presence  of  IL-1  and/or  TNF-.
.3.  COX-2  (PTGS2)
yclooxygenase  (COX)  -2,  also  known  as  prostaglandin-
ndoperoxide synthase  2  (PTGS2),  was  ranked  8  among
he top  10  up-regulated  genes  in  FLS  treated  with  IL-1
Table 1).  In  contrast,  COX-2  was  not  observed  among  the
op 10  up-regulated  genes  with  TNF-,  although  it  was  rank
7 (data  not  shown).
COXs  are  the  rate-limiting  enzyme  in  the  synthesis  of
iological mediators  known  as  prostanoids,  consisting  of
16  N.  Ogura,  T.  Kondoh
Figure  3  Gene  expression  of  IL-6  and  IL-6  receptors.  The  gene
expression of  IL-6  and  IL-6R,  and  gp  130  was  examined  in  FLS
treated with  or  without  IL-1  and/or  TNF-  for  4  h  by  RT-PCR.
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Table  3  Expressions  of  EP  receptor  (EP1—4)  genes  in  FLS
by microarray.
Normalized  intensity
EP1  EP2  EP3  EP4
Control  A  8.51  ±  0.94  A  6.57  ±  0.37
IL-1 A  9.50  ±  0.82  A  7.07  ±  1.47
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TNF- (Table  3).  The  agonists  of  EP2  and  EP4,  and  PGE2
stimulate  the  production  of  IL-6  in  FLS  (Fig.  4)  [19].  EP4
receptor was  partially  effective  with  regard  to  IL-6  produc-
tion in  FLS  mediated  by  PGE2, as  indicated  by  treatment
Figure  4  Effects  of  EP  agonists  on  IL-6  production.  Time
course of  IL-6  protein  production  in  the  conditioned  medium
of FLS  was  determined  by  ELISA.  Cells  were  cultured  with  or
without PGE2  or  EP  receptor  agonists,  and  were  incubated
for 4,  8,  12  or  24  h.  ()  None,  ()  PGE2,  ()  EP1  agonist, control;  I,  IL-1;  T,  TNF-;  I  +  T,  IL-1  +  TNF-.
ource: Kawashima  et  al.  [75].
rostaglandin  (PG)  D2,  PGE2,  PGF2a,  prostacyclin  PGI2 and
hromboxane A2 [76].  Following  cellular  activation,  arachi-
onic acid  (AA)  is  released  from  membrane  phospholipids
y phospholipase  A2 and  is  then  converted  to  the  PGs  inter-
ediate PGH2 by  COXs.  Short-lived  PGH2 is  then  quickly
onverted to  ﬁve  prostanoids  by  each  prostanoid  synthase.
OX-1 is  a  constitutive  enzyme  in  the  majority  of  cells.  In
ontrast, COX-2  is  inducible  in  response  to  inﬂammation,  its
ene expression  can  be  induced  by  multiple  cytokines  and
rowth factors,  via  activation  of  transcriptional  regulatory
roteins that  act  on  the  promoter  sites,  such  as  NFkB,  AP1
nd C/EBP  [77,78].  COX-3  is  a  splice  variant  of  COX-1  [79].
PGE2 is  the  most  studied  member  of  the  eicosanoid
amily and  is  generated  from  unsaturated  20-carbon  fatty
cids such  as  AA,  playing  a  pivotal  role  in  inﬂammation
y mediating  local  dilatation  of  blood  vessels,  increasing
lood vessel  permeability  and  sensitizing  peripheral  noci-
eptors [80].  PGE2 exerts  a  range  of  biological  activities
hat include  stimulation  of  inﬂammation-associated  bone
esorption [81].  The  major  effect  of  PGE2 on  resorption  is
enerally considered  to  occur  indirectly  via  up-regulation
f RANKL  expression  and  by  inhibition  of  OPG  expression
n osteoblastic  cells,  although  it  has  been  reported  that
GE2 has  both  stimulatory  and  inhibitory  effects  on  RANKL-
timulated osteoclast  formation  [81].
PGE2 contributes  to  the  pathogenesis  of  several  chronic
nﬂammatory conditions,  including  periodontitis,  RA  and
ardiovascular inﬂammatory  disease.  High  concentrations  of
GE2 have  been  detected  in  the  synovial  ﬂuid  of  patients
ith OA  and  RA  [82,83].  PGE2 has  also  been  found  in  TMJ
ynovial ﬂuids  from  patients  with  ID,  and  is  associated
ith synovitis  index  based  on  synovial  membrane  hyper-
mia as  the  diagnostic  criteria  for  TMJ  arthroscopy  [84,85].
t has  been  reported  that  cytokine-activated  cells,  such  as
ynovial cells,  chondrocytes  and  macrophages/monocytes,
re the  primary  source  of  PGE2 in  arthritic  joints.  PGE2
roduction  at  sites  of  inﬂammation  coincides  with  the  up-
egulation of  COX-2  expression  in  articular  cells  activating
ro-inﬂammatory factors  [86].
(
n
*
STNF- A  10.17  ±  0.26  A  6.76  ±  1.37
N = 3; A, absent.
The  existence  of  four  EP  receptor  subtypes  (EP1—4)
ncoded by  distinct  genes  also  contributes  to  the  diversity
f the  biological  activity  of  PGE2 [87].  EP1  acts  largely  by
ncreasing calcium  ﬂux  but  perhaps  also  via  protein  kinase  C
PKC)  [88].  Although  it  might  be  coupled  to  Gq,  the  absence
f a  phosphatidylinositide  response  has  led  to  speculation
hat it  is  coupled  to  an  as  yet  unidentiﬁed  G  protein  [87].
oth EP2  and  EP4  are  coupled  to  Gs  and  stimulate  cyclic  3,5-
denosine monophosphate  (cAMP)  formation  [89,90].  EP3  is
oupled to  Gi  and  acts  largely  by  inhibiting  cAMP  production
91]. FLS  from  patients  with  RA  and  OA  mainly  expressed  EP2
nd EP4  [92].  A  previous  study  has  shown  that  PGE2 increased
he production  of  pro-inﬂammatory  cytokines  such  as  IL-6
nd VEGF  in  FLS  with  RA  and  OA  through  the  activation  of
P2 and  EP4,  and  with  increases  in  cAMP  [92].  These  ﬁndings
uggest that  elevated  PGE2 production  is  associated  with
nﬂammatory joint  diseases,  and  can  lead  to  bone  loss.
On  microarray  analysis,  EP2  and  EP4  were  expressed  in
LS from  patients  with  ID  TMJ,  and  the  expression  of  EP2
nd EP4  was  slightly  elevated  in  FLS  treated  with  IL-1  orONO-DI-004),  ()  EP2  agonist  (ONO-AE-259-1),  ()  EP3  ago-
ist  (ONO-AE-248),  (×)  EP4  agonist  (ONO-AE1-329),  *P  <  0.05,
*P <  0.01,  ***P  <  0.005.
ource:  Kawashima  et  al.  [19].
Inﬂammatory  mediators  in  TMJ  17
Figure  5  Effect  of  COX  inhibitors  on  IL-6.  The  levels  of  IL-6  gene  expression  in  FLS  were  determined  by  real-time  PCR.  The  cells
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Source:  Kawashima  et  al.  [19].
with  EP4  agonist.  Expression  of  EP4  receptor  was  at  a
lower level  than  that  of  the  EP2  receptor  (Table  3),  and
was transiently  enhanced  by  IL-1  [19].  PGE2  affects  IL-
6 production  through  EP2  and  EP4  in  the  FLS.  In  addition,
COX inhibitors  (indomethacin  or  celecoxib)  decreased  the
expression of  IL-6  in  FLS  stimulated  with  IL-1  (Fig.  5)  [19].
Our results  suggest  that  COX  inhibitors  as  non-steroidal  anti-
inﬂammatory drugs  (NSAIDs)  are  useful  for  treating  synovitis
in TMJ  through  the  suppression  of  both  PGE2 and  inﬂamma-
tory mediators  such  as  IL-6.
4.4.  GM-CSF  (CSF2)
Granulocyte  macrophage  colony  stimulating  factor  (GM-
CSF), also  known  as  colony  stimulating  factor-2  (CSF2),  was
observed among  the  top  10  up-regulated  genes  in  FLS  with
inﬂammatory stimulation,  and  ranked  3  with  both  IL-1-
stimulation and  TNF--stimulation  (Table  1).  GM-CSF  was
originally deﬁned  as  a  hemopoietic  growth  factor  [93].  How-
ever, it  is  able  to  act  on  mature  myeloid  cells  and  has  other
functions, acting  as  a  pro-inﬂammatory  cytokine  [94].  GM-
CSF  inﬂuences  dendritic  cells  and  macrophage  recruitment
into inﬂammatory  sites  [95].  GM-CSF  is  also  important  for
effective antigen  processing  and  presenting  function  in  anti-
gen present  cells  (APC)  [96].  Recent  studies  have  highlighted
a surprising  role  for  GM-CSF  responsive  monocyte-derived
dendritic cells  in  the  pathogenicity  of  Th17  cells,  which  are
important mediators  for  inﬂammatory  diseases  [97].  More-
over, IL-17  produced  by  activated  Th17  induced  the  GM-CSF
production from  macrophages  [98].
GM-CSF  is  produced  by  a  wide  variety  of  cell  types,
including activated  T-cells,  B-cells,  macrophages,  endothe-
lial cells  and  ﬁbroblasts,  and  its  production  is  increased  by
inﬂammatory factors  such  as  IL-1,  TNF  and  PGE2.  GM-CSF
is detected  abundantly  in  RA  synovial  ﬂuid  and  is  scarcely
detected in  non-inﬂammatory  synovial  ﬂuid  [99].  GM-CSF
was also  detected  in  synovial  ﬂuids  from  patients  with  ID
and/or OA  of  TMJ,  but  was  not  detected  in  normal  controls
[100].
GM-CSF was  detected  in  the  erosive  inﬂammatory  reac-
tion around  orthopedic  implants  [101]  and  in  osteolytic  bone
metastasis  from  malignant  tumors  [102].  However,  studies
R
c
c
ped  for  4  and  12  h.  *P  <  0.05.
xamining  the  effects  of  GM-CSF  on  osteoclastogenesis  have
eported contradictory  results.  It  has  been  reported  that
M-CSF induced  the  fusion  of  prefusion  osteoclasts  to  form
ultinucleated osteoclasts,  making  the  osteoclast  capable
f bone  resorption  [103].  In  contrast,  another  study  demon-
trated that  GM-CSF  abolished  monocytic  differentiation
nto osteoclasts  while  inducing  DC  differentiation  even  in
he presence  of  M-CSF  and  RANK  ligand  [104].  Although  the
asis for  these  apparently  contradictory  results  reached  by
hese different  approaches  is  unclear,  this  uncertainty  as  to
he effects  of  GM-CSF  on  osteoclast  differentiation  may  be
elated to  the  stages  for  osteoclast  differentiation  and/or
he potential  signiﬁcance  of  its  increased  production  at  sites
f inﬂammation.
.5.  BCL2A1
-cell  lymphoma  2-related  protein  A1  (BCL2A1),  also  known
s Bcl-2-related  gene  expressed  in  fetal  liver  (Bﬂ-1),  is
mong the  top  10  up-regulated  genes  in  FLS  with  inﬂam-
atory stimulation,  ranked  9 with  IL-1-stimulation  and
anked 7  with  TNF--stimulation  (Table  1).  BCl2A1  is  a  mem-
er of  the  B-cell  lymphoma  2  (BCL2)  protein  family,  which
re important  cell  death  regulators  [105].  The  BCL2  fam-
ly comprises  both  pro-  and  anti-apoptotic  proteins  [106].
CL2A1 is  an  anti-apoptosis  protein  of  the  BCL2  family  whose
ain function  is  binding  to  pro-apoptosis  BCL2  members
uch as  BAK,  and  then  inhibiting  BAK  function  [106,107].  Pro-
poptosis proteins  induce  the  release  of  cytochrome  c  from
itochondria, caspase  activation  and  apoptosis  [106,107].
herefore, BCL2A1,  similarly  to  BCL2,  is  an  anti-apoptotic
CL2 protein  to  control  the  release  of  cytochrome  c  from
itochondria in  the  intrinsic  apoptotic  pathway.  In  addition,
CL2A1 is  a highly  regulated  NFB  target  gene  that  exerts
mportant pro-survival  functions  [108].
In  a  physiological  context,  BCL2A1  is  mainly  expressed
n the  hematopoietic  system,  where  it  facilitates  survival
f selected  leukocytes  subsets  and  inﬂammation  [106].  In
A, the  synovium  is  inﬁltrated  by  chronic  inﬂammatory
ells, such  as  macrophages,  dendritic  cells,  and  lympho-
ytes [109].  The  resident  ﬁbroblasts  adopt  a  quasi-malignant
henotype with  up-regulation  of  oncogenes,  inhibition  of
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poptosis,  and  secretion  of  cytokines,  chemokines,  and
nzymes, which  reinforce  inﬂammation  and  catalyze  joint
estruction. This  suggests  the  necessity  of  further  evalua-
ion of  the  role  of  BCL2  in  RA  and,  in  particular,  a  potentially
verlooked role  for  long-term  survival  of  inﬂammatory  cells
106]. To  the  best  of  our  knowledge,  there  have  been  no
eports of  BCL2A1  being  detected  in  synovium  or  being
xpressed in  FLS  from  inﬂammatory  joint  diseases.
On  microarray,  expression  of  BCL2A1  was  elevated  in
LS-treated IL-1.  We  also  found  that  the  intimal  layer  of
ynovial tissue  was  hypertrophic  in  rat  TMJ  after  in  vivo
njection of  IL-1.  This  suggests  that  BCL2A1  is  associated
ith hypertrophy  of  the  synovial  layer,  although  there  have
een no  reports  of  BCL2A1  detection  in  the  synovial  tissue
f ID  and  OA  TMJ.
.6.  ICAM1
ntercellular  Adhesion  Molecule  1  (ICAM1)  was  ranked  4
mong the  top  10  up-regulated  genes  in  FLS  treated  with
NF- (Table  1).  In  contrast,  ICAM1  was  not  observed  among
he top  10  up-regulated  genes  with  IL-1  (it  was  ranked  12;
ata not  shown).  ICAM1  is  a  member  of  the  immunoglobu-
in superfamily  of  adhesion  molecules  mediating  the  contact
etween two  cell  types,  or  between  cells  and  the  extracellu-
ar matrix  [110].  ICAM1  is  expressed  in  numerous  cell  types,
ncluding leukocytes,  macrophages,  dendritic  cells,  ﬁbro-
lasts, endothelial  and  epithelial  cells.  ICAM1  is  scarcely
etectable in  normal  cells,  but  its  expression  is  enhanced
n FLS,  chondrocytes  and  endothelial  cells  in  response  to
nﬂammatory cytokines  such  as  TNF-,  IL-1  and  IFN-
111]. ICAM-1  was  detected  in  synovium  and  cartilage  from
A patients  [112].  ICAM-1  also  mediates  the  inﬁltration  of
eucocytes by  recognition  with  ligand  lymphocyte  function-
ssociated antigen-1  (LFA-1)  [113].  It  has  been  suggested
hat activation  of  RA  synovial  ﬁbroblasts  with  inﬂammatory
ytokines stimulates  the  synthesis  and  expression  of  adhe-
ion molecules  such  as  ICAM-1,  which  facilitate  recruitment
nd retention  of  inﬂammatory  cells  in  the  synovium  resulting
n joint  inﬂammation.
A fragment  of  ICAM-1  found  in  the  circulation  (sICAM-1)
s thought  to  be  cleaved  from  the  surface  of  ICAM-1-
xpressing cells  [110].  This  adhesion  molecule  plays  critical
oles in  several  different  inﬂammatory  and  immunologic
rocesses. Synovial  ﬂuids  from  patients  with  RA  and  other
nﬂammatory arthritides  had  signiﬁcantly  higher  sICAM-1
evels when  compared  with  osteoarthritis  (OA)  synovial  ﬂu-
ds [114].  Synovial  ﬂuid  sICAM-1  levels  were  signiﬁcantly  and
ositively correlated  with  synovial  ﬂuid  leukocyte  counts.
oluble level  of  ICAM1  in  sera  and  synovial  ﬂuid  (SF)  are
orrelated with  some  clinical  parameters  and  synovial  tis-
ue expression  of  ICAM1  in  RA  [115].  It  has  been  shown
hat sICAM1  is  able  to  bind  to  LFA-1  and  competitively
nhibit ICAM-1/LFA-1-mediated  cell—cell  interaction  in  vitro
116], albeit  at  concentrations  much  greater  than  those
ound in  plasma.  As  a  consequence,  it  is  unlikely  that
ICAM1 antagonizes  ICAM1/LFA-1-mediated  cellular  events
n vivo.  To  the  best  of  our  knowledge,  there  have  been  no
eports of  the  detection  of  ICAM1  and  sICAM1  in  ID  and  OA
MJ.
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.7.  GCH1
uanosine  triphosphate  (GTP)  cyclohydrolase  I (GCH1)  was
anked 8  among  the  top  10  up-regulated  genes  in  FLS  treated
ith TNF-  (Table  1).  In  contrast,  GCH1  was  not  observed
mong the  top  10  up-regulated  genes  with  IL-1  (it  was
anked 15;  data  not  shown).  GCH1  catalyzes  the  conver-
ion of  GTP  to  D-erythro-7,8-dihydroneopterin  triphosphate,
he ﬁrst  and  rate-limiting  step  in  tetrahydrobiopterin  (BH4)
iosynthesis [117].  It  has  been  demonstrated  that  GCH1  is  a
ey modulator  of  peripheral  neuropathic  and  inﬂammatory
ain. BH4  represents  an  essential  cofactor  for  the  produc-
ion of  catecholamines,  serotonin  and  nitric  oxide  [118],
ll of  which  are  heavily  implicated  in  the  pathogenesis  of
igraines [119].  After  axonal  injury,  concentrations  of  BH4
ose in  primary  sensory  neurons,  owing  to  up-regulation  of
CH1. After  peripheral  inﬂammation,  BH4  also  increased  in
orsal root  ganglia,  owing  to  enhanced  GCH1  enzyme  activ-
ty. Recently,  it  has  been  shown  that  carriers  of  a  particular
aplotype of  GCH1  had  decreased  sensitivity  to  some  exper-
mental mechanical  pain  stimuli  [120].  While  recent  data
uggest a  ‘‘protective’’  (less  pain)  haplotype  in  the  GCH1
ene, other  research  has  failed  to  conﬁrm  this  association.
o the  best  of  our  knowledge,  although  there  have  been  no
eports for  GCH1  in  joint  diseases,  GCH1  may  be  associated
ith pain  in  joint  diseases.  Further  studies  on  GCH1  in  joint
iseases such  as  RA  and  OA  are  therefore  necessary.
.8.  IL17RB
L-17  receptor  B  (IL17RB)  was  ranked  9  among  the  top  10
p-regulated genes  in  FLS  treated  with  TNF-  (Table  1).  In
ontrast, IL17RB  was  not  among  the  top  10  up-regulated
enes with  IL-1  (it  was  ranked  16;  data  not  shown).  IL17RB
s one  of  IL-17  receptor  family  members  that  now  consist
f 5  members  (IL17RA,  IL17RB,  IL17RC,  IL17RD  and  IL17RE).
n contrast,  the  IL-17  ligand  family  comprises  6  members;
L-17A, IL-17B,  IL-17C,  IL-17D,  IL-17E  (also  called  IL-25)  and
L-17F [121].  IL-17  typically  refers  to  IL-17A.  IL-17A  is  well
haracterized as  a  signature  cytokine  that  participates  in
oth acute  and  chronic  inﬂammatory  responses,  while  the
ther forms  have  not  been  widely  studied  [122].  IL-17A,
hich is  produced  by  Th17  helper  cells,  plays  a  pathological
ole in  inﬂammatory  and  autoimmune  diseases.  High  IL-17A
evels have  been  observed  in  patients  with  autoimmune
iseases such  as  RA  [123].  Previous  studies  have  reported
hat IL-17A  stimulation  leads  to  TRAF  6  recruitment  to  the
L17RA-IL17RC receptor  heterodimer  complex,  and  induces
FB activation  [121].
Recent  reports  have  shown  that  IL-17E  (IL-25)  and  IL-
7B have  an  afﬁnity  for  IL17RB  [121,124].  IL-17E  signaling
hrough the  IL-17RA-IL17RB  receptor  heterodimer  complex
nduces Th2  responses  by  activating  the  MAPK  and  NFB
athways. IL-17E  is  produced  by  eosinophils,  mast  cells  and
irway epithelial  cells  and  stimulates  asthma-like,  allergic
nﬂammation [121,125].  On  the  other  hand,  IL-17B,  which  is
xpressed in  chondrocytes  [126],  has  been  shown  to  interact
ith IL-17RB  [121];  however,  its  biological  function  remains
nclear.
The IL-17  cytokine  family,  derived  from  a wide  array  of
ell types,  coupled  to  the  differential  expression  of  their
Inﬂammatory  mediators  in  TMJ  19
Figure  6  Gene  expression  and  protein  production  of  M-CSF.
FLS were  treated  with  100  pg/ml  IL-1.  A.  Gene  expression  of  M-
CSF in  FLS  treated  with  or  without  IL-1  using  RT-PCR.  B.  Protein
production of  M-CSF  in  FLS  with  ()  or  without  ()  IL-1.  n  =  3,
Figure  7  Canonical  pathway  of  NFB  activation  through  IL-1
or TNF-  signaling.  Shading  of  the  nodes  shows  the  average  level
of gene  expression  in  FLS  from  ﬁve  patients  as  determined  by
microarray analysis.  The  highest  levels  of  expression  correspond
to shading.  Shading  in  the  left  part  of  a  molecule  shows  the
relative levels  of  expression  in  controls,  and  shading  in  the  right
part shows  the  relative  levels  of  expression  in  IL-1-stimulated
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Source:  Ito  et  al.  [127].
receptors  on  various  cells  and  tissues,  illustrate  the  com-
plexity of  the  cytokine  family  network  in  modulating  the
immune response  and  inﬂammation.  Further  studies  into  the
role of  IL17RB  in  joint  diseases  such  as  RA  and  OA  remain
necessary.
4.9.  Other  molecules
We  have  reported  several  IL-1-responsive  genes  other  than
the top  10  genes  up-regulated  in  FLS  by  IL-1-  and/or  TNF-
. The  expression  and  the  production  of  monocyte  colony
stimulating factor  (M-CSF),  also  known  as  CSF1,  which  was
ranked 26  with  IL-1-stimulation  and  was  ranked  22  with
TNF--stimulation (data  not  shown),  was  increased  in  FLS
treated with  IL-1  (Fig.  6),  and  was  detected  in  the  synovial
tissues of  the  IL-1-injected  TMJ  in  rats  [127].  M-CSF  is  crit-
ical for  the  proliferation  and  survival  of  macrophages  and
osteoclast precursors  [128,129].
In  contrast,  gene  expressions  of  inhibitor  B  (IB),
TNF--induced protein  3,  (TNFAIP3,  also  known  as  A20),
TNFAIP3-interacting protein  1  (TNIP1,  also  known  as  ABIN1;
A20-binding inhibitor  of  NFB1),  and  cellular  inhibitors  of
apoptosis (c-IAP,  also  known  as  BIRC;  baculoviral  IAP  repeat-
containing protein),  which  inhibit  NFB  activation,  were
also increased  after  IL-1  treatment  in  FLS  (Fig.  7)  [130].
IB was  ranked  64  with  IL-1-stimulation  and  ranked
42 with  TNF--stimulation.  TNFAIP3  was  ranked  27  with
IL-1-stimulation and  ranked  19  with  TNF--stimulation.
TNIP1 was  ranked  78  with  IL-1-stimulation  and  ranked  55
o
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ource: Kishida  et  al.  [130].
ith  TNF--stimulation.  c-IAP2  was  ranked  25  with  IL-1-
timulation and  ranked  28  with  TNF--stimulation.  The  gene
xpression of  these  inhibitors  of  NFB  activation  was  rapidly
nduced by  NFB  in  a  negative  feedback  loop  that  may  main-
ain a  transient  NFB  response.
.  Conclusion
his  review  focused  on  the  molecules  that  are  enhanced  in
LS treated  with  IL-1  and/or  TNF-  based  on  microarray
nalysis, and  summarized  their  functions  based  on  recent
tudies. It  is  notable  that  the  expression  of  chemokines  and
dhesion molecules  is  up-regulated  in  FLS  after  stimulation
ith IL-1  or  TNF-.  Previous  reports  have  shown  that  syn-
vitis is  characterized  by  inﬁltration  of  inﬂammatory  cells,
nd increases  in  new  capillaries  and  small  vessels.  Similarly,
everal molecules  categorized  as  inﬂammatory  factors,
atabolic enzymes,  osteoclast  differentiation  factors,
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Figure  8  Schema  of  synovitis  progression.  When  levels  of  IL-1  and/or  TNF-  are  increased  in  synovial  ﬂuids,  FLS  increase
production of  chemokines,  adhesion  molecules  and  CFSs.  These  factors  produced  by  FLS  stimulate  chemotaxis  of  neutrophils,
macrophages and  T-lymphocytes,  and  these  inﬂammatory  cells  produce  inﬂammatory  cytokines  such  as  IL-1,  matrix  degradative
enzymes  and  various  products  of  oxidative  metabolism.  These  enzymes  and  oxidative  metabolites  cause  degradation  of  extracellular
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Ratrix,  and  inﬂammatory  cytokines  stimulate  FLS  to  produce  
atabolic  enzymes.
ociceptors  and  signal  transducers  were  also  up-regulated
n FLS  on  microarray  analysis.  Previously,  the  gene  expres-
ion of  catabolic  enzymes  such  as  MMP-1,  -2  and  -3,  and
DAMTS-4 and  -5  was  conﬁrmed  to  be  up-regulated  in  FLS
fter mechanical  stress  [131].  This  suggests  that  excess
echanical compressive  stress  such  as  clenching  or  brux-
sm up-regulates  the  mRNA  expression  of  MMPs  and  ADAMSTs
n FLS,  and  induces  inﬂammation  and  tissue  degradation  in
ynovium, and  may  then  promote  osteoarthritis  of  the  TMJ
131]. In  addition,  M-CSF,  which  is  critical  for  the  prolifera-
ion and  survival  of  macrophages  and  osteoclast  precursors,
as up-regulated  in  FLS  treatment  with  IL-1  and  TNF-.
hese regulated  genes  may  be  associated  with  the  pathol-
gy of  painful  and  dysfunctional  ID  or  OA  in  TMJ.  Our  data
upport the  notion  that  one  of  the  reasons  behind  synovitis
nduction is  the  increased  levels  of  IL-1  and/or  TNF-  in
he synovial  ﬂuids  of  patients  (Fig.  8).
Among  the  top  10  up-regulated  factors,  most  molecules
re well  characterized  and  have  been  investigated  in  the
nﬂammatory responses  and  tissue  destruction  associated
ith joint  diseases  such  as  RA  and  OA,  but  some  molecules
uch as  GCH1  remain  unclear.  Recently,  numerous  molecules
ave been  detected  by  in  silico  identiﬁcation  using  genetic
atabases. For  instance,  the  IL-1  family  has  grown  impres-
ively in  size,  complexity  and  division  of  labor.  IL-1  family
igands include  seven  molecules  with  agonist  activity  (IL-
, IL-1,  IL-18,  IL-33,  IL-36,  IL-36  and  IL-36),  three
eceptor antagonists  (IL-1Ra,  IL-36Ra  and  IL-38)  and  an  anti-
nﬂammatory cytokine  (IL-37)  [132].  These  new  cytokines
nd their  associated  signaling  pathways  have  been  impli-
ated in  the  pathogenesis  of  RA,  and  could  be  targeted
o offer  new  therapeutic  options  for  RA  therapy.  Currently,
umerous underlying  pathways  remain  unknown,  but  recent
fforts have  begun  to  increase  our  understanding.  Nev-
rtheless, better  understanding  of  these  interactions  ande  pro-inﬂammatory  cytokines,  such  as  chemokines,  PGE2  and
ignaling  in  inﬂammatory  and  dysfunctional  settings  will  be
rucial for  the  discovery  of  new  therapeutic  targets  that  will
nable us  to  design  more  suitable  treatments  for  patients
ho do  not  respond  to  conventional  therapies.
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